The association of humoral antigen spread (AgS) with cytotoxic T lymphocyte (CTL) activity after sipuleucel-T (sip-T) treatment in two phase II clinical studies: STAMP and STRIDE.

Daniel P. Petrylak,Emmanuel S. Antonarakis,Harini Kandadi,Lawrence Fong,Raymond S. Lance,Tuyen Vu,Nadeem A. Sheikh,Neal D. Shore,Charles G. Drake

The association of humoral antigen spread (AgS) with cytotoxic T lymphocyte (CTL) activity after sipuleucel-T (sip-T) treatment in two phase II clinical studies: STAMP and STRIDE.

2020

Daniel P. Petrylak
Emmanuel S. Antonarakis
Harini Kandadi
Lawrence Fong
Raymond S. Lance
Tuyen Vu
Nadeem A. Sheikh
Neal D. Shore
Charles G. Drake

112Background: Sip-T is an FDA-approved immunotherapy for metastatic castration-resistant prostate cancer. Sip-T generates CTL and humoral antigen activity, as measured by CD107a expression on PAP ...

Keywords:

Prostate cancer
Immunotherapy
Sipuleucel-T
STRIDE
CTL*
Pathology
Antigen
Cytotoxic T cell
Immunology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations